ODQ

• Description :

  ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Guanylate Cyclase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; GPCR/G Protein

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/odq.html

• Purity :

  99.75

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1ON=C2N1C3=C(C=CC=C3)N=C2

• Molecular Formula :

  C9H5N3O2

• Molecular Weight :

  187.16

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ronald Fiscus, et al. ODQ, an inhibitor of soluble guanylyl cyclase (nitric oxide-activated enzyme), enhances the pro-apoptotic effects of cisplatin in human mesothelioma cells. Cancer Res May 1 2007 (67) (9 Supplement) LB-43.|[2]Zacharowski K, et al. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med. 2001;29 (8) :1599-1608.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [41443-28-1]